Atlas Trials

Tesetaxel Plus Reduced Dose of Capecitabine in Patients With HER2 Negative, HR Positive, LA/MBC

Clinical trial NCT03858972 · TERMINATED

Trial details

NCT number
NCT03858972
Sponsor
Odonate Therapeutics, Inc.
Status
TERMINATED
Phase
Phase 2
Study type
INTERVENTIONAL
Breast Cancer
Start date
2019-02-05
Primary completion
2021-06-11
Enrollment
152

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.